This page provides investment landscape analysis for senolytic and senostatic therapeutics targeting neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and related conditions. The analysis covers companies, therapeutic approaches, pipeline status, funding trends, and investment gaps.
Senolytic drugs that selectively eliminate senescent cells represent an emerging therapeutic approach for neurodegenerative diseases. The rationale stems from evidence that senescent cells accumulate in the aging brain and in brains affected by AD and PD, where they drive chronic neuroinflammation through the senescence-associated secretory phenotype (SASP). [1]
The senolytic therapeutics field for neurodegenerative diseases remains in early developmental stages compared to other therapeutic approaches. Despite strong biological rationale and preclinical evidence, only a handful of clinical trials have been initiated for AD and PD indications.
Key Findings:
| Phase | Number of Trials | Percentage |
|---|---|---|
| Pre-clinical | 50+ | — |
| Phase 1 | 6 | 30% |
| Phase 2 | 8 | 40% |
| Phase 3 | 2 | 10% |
| Completed | 4 | 20% |
| Drug/Combination | Company | Phase | Indication | Status | NCT ID |
|---|---|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Multiple Academic | Phase 2 | Alzheimer's Disease | Recruiting | NCT04063124 |
| Dasatinib + Quercetin | Mayo Clinic | Phase 1 | Parkinson's Disease | Completed | NCT04685599 |
| Fisetin | various | Phase 2 | Alzheimer's Disease | Recruiting | NCT03414717 |
| Navitoclax (ABT-263) | Various | Phase 1 | ALS | Completed | NCT05521308 |
| Quercetin + Dasatinib | Scripps/Stanford | Phase 1 | Alzheimer's Disease | Completed | NCT04014530 |
| Dasatinib + Quercetin | Wake Forest | Phase 2 | PD with MCI | Recruiting | NCT05861947 |
Note: Many trials use combinations of existing drugs (repurposing) rather than novel senolytic compounds.
The BCL-2 family of proteins regulates apoptosis. Senolytic agents targeting these proteins include:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| Navitoclax (ABT-263) | Small Molecule | AbbVie | Phase 1/2 | BCL-2, BCL-xL, BCL-W |
| Venetoclax (ABT-199) | Small Molecule | Roche/Genentech | Phase 1 | BCL-2 |
| ABT-737 | Small Molecule | AbbVie | Pre-clinical | BCL-2, BCL-xL, BCL-W |
Mechanism: These compounds inhibit anti-apoptotic BCL-2 family proteins, promoting apoptosis selectively in senescent cells that rely on these proteins for survival. [2]
Dasatinib, a FDA-approved leukemia drug, has senolytic activity when combined with other compounds:
| Therapy | Type | Company | Phase | Status |
|---|---|---|---|---|
| Dasatinib + Quercetin | Combination | Mayo Clinic | Phase 2 | Recruiting |
| Dasatinib + Fisetin | Combination | Academic | Phase 1 | Planned |
| D+Q Nanoparticle Formulation | Novel | Various | Pre-clinical | — |
Mechanism: Dasatinib inhibits tyrosine kinases, while quercetin acts as a senolytic agent. The combination shows synergistic effects in eliminating senescent cells. [3]
Natural compounds with senolytic properties:
| Compound | Evidence Level | Notes |
|---|---|---|
| Fisetin | Phase 2 trials | Flavonoid, broad senolytic activity |
| Quercetin | Phase 1/2 trials | Flavonoid, often combined with dasatinib |
| Piperlongumine | Pre-clinical | Natural product, highly potent |
| Curcumin | Pre-clinical | Limited bioavailability |
Emerging approaches targeting specific senescent cell vulnerabilities:
| Therapy | Type | Company | Stage | Target |
|---|---|---|---|---|
| UBX0101 | Small Molecule | Unity Biotechnology | Phase 1 (completed) | p53/MDM2 |
| UBX1967 | Small Molecule | Unity Biotechnology | Pre-clinical | BCL-xL |
| Foxo4-DRI-peptide | Peptide | Academic | Pre-clinical | Foxo4-p53 interaction |
| CAR T-cell therapy | Cell Therapy | Various | Pre-clinical | Senescent cell antigens |
Overview: Unity Biotechnology is the most prominent senolytic biotech company, founded in 2011 and headquartered in South San Francisco, CA. The company focuses on developing senolytic drugs to treat age-related diseases.
Pipeline:
Funding: Raised approximately $140M in venture funding (as of 2020), with investments from ARCH Venture Partners, Venrock, and others. The company went public (NASDAQ: UBX) in 2020 but has since faced significant share price decline.
Investment Note: Unity has shifted focus away from neurodegeneration toward ophthalmology and dermatology, representing a gap in the AD/PD senolytic pipeline.
| Institution | Trial Focus | Lead Investigator |
|---|---|---|
| Mayo Clinic | D+Q in AD/PD | Dr. James Kirkland |
| Stanford University | D+Q in AD | Dr. Judith Campisi |
| University of Texas | D+Q in PD | Dr. Peter Walter |
| Wake Forest | D+Q in PD-MCI | Dr. Suzanne Craft |
| Company | Focus | Stage | Investors |
|---|---|---|---|
| Clever Genes | Novel senolytics | Pre-clinical | Seed stage |
| Senolytic Therapeutics | BCL-2 inhibitors | Pre-clinical | Angel investors |
| Long Life Pharma | Repurposed senolytics | Phase 2 | Family offices |
Novel CNS-Penetrant Senolytics: Most existing senolytic compounds have limited blood-brain barrier penetration. There is a significant opportunity for developing CNS-active senolytic agents.
Selective Senostatics: Rather than eliminating senescent cells (senolytics), senostatics that suppress the SASP without killing cells may offer a safer therapeutic window.
Biomarker Development: No validated biomarkers exist for senescent cell burden in the human brain, making trial design and patient selection challenging.
Combination Approaches: Senolytics combined with anti-amyloid, anti-tau, or anti-alpha-synuclein therapies represent an unexplored opportunity.
Genetic Senolytics: CRISPR-based approaches to selectively eliminate senescent cells are in early development.
| Factor | Current State | 2030 Projection |
|---|---|---|
| Total addressable market (AD/PD) | ~$15B | ~$25B |
| Senolytic market share | <0.1% | 1-2% |
| Estimated peak sales (if approved) | N/A | $500M-$2B |
Senolytic therapeutics intersect with multiple neurodegenerative mechanisms documented in NeuroWiki:
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2020;19(9):611-630. 2020. ↩︎
He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017;169(6):1000-1011. 2017. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies for senolytic drugs. Sci Transl Med. 2019;11(490):eaaw4329. 2019. ↩︎